- Home
- CRIS vs LNAI Comparison
CRIS vs LNAI Comparison
Compare CRIS & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | LNAI |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 11.9M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRIS | LNAI |
|---|---|---|
| Price | $0.58 | $0.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 657.5K | ★ 4.2M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $67.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.49 | $0.15 |
| 52 Week High | $3.13 | $1.66 |
Technical Indicators
Market Signals| Indicator | CRIS | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 47.90 |
| Support Level | $0.51 | $0.27 |
| Resistance Level | $0.79 | $0.54 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 43.91 | 47.94 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About LNAI Lunai Bioworks Inc.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.